Ocumetics Lens restores vision for legally blind patients in groundbreaking trial

Ocumetics Lens restores vision for legally blind patients in groundbreaking trial

A diagram of a human eye with a lens and a pupil, illustrating the process of conjunctivitis, with accompanying text detailing the procedure.

Ocumetics Lens restores vision for legally blind patients in groundbreaking trial

Ocumetics has announced promising results from its first-in-human study of the Ocumetics Lens. The trial involved patients with severe visual impairment, some legally blind before surgery. Early findings show the lens has improved vision and daily life for those treated so far.

Group 1 of the study included patients with uncorrected vision as poor as 20/250—levels classified as legal blindness. Despite the severity of their conditions, the lens met all safety benchmarks and exceeded expectations for visual acuity. It also performed well in delivery and foundational distance vision.

Dean Burns, CEO of Ocumetics, expressed strong confidence in the technology after reviewing the data. He highlighted its potential to restore independence for those with severe vision loss. Dr. Rafael Vázquez, the study's lead investigator, added that patients experienced life-changing improvements, regaining abilities like reading, driving, and enjoying daily activities.

The company is now preparing for Group 2 surgeries. Manufacturing of refined lens designs is underway, with final testing and validation required before the next phase begins. Ocumetics continues its rapid research approach, using feedback from Group 1 to optimize performance.

Burns will host a webinar on 11 September to discuss the three-month results and updates on the study. The event is open to registrants via the company's website.

The Ocumetics Lens has cleared key safety and performance targets in its first human trials. Patients who once faced legal blindness now report significant gains in vision and quality of life. With Group 2 surgeries planned, the company aims to build on these early successes.

Neueste Nachrichten